EUVIMEDEUVIMED entdecken
Crossref

Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents

Tsuyoshi Inoue iD, Daisuke Watabe iD, Yuichiro Tsunemi iD, Hiroo Amano

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Tsuyoshi Inoue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Iwate Medical University School of Medicine, Iwate, Japan. Hauptthemen laut MEDLINE: Onychomycosis, Dermatologic Agents, Foot Dermatoses. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fosravuconazole L‐lysine ethanolate (F‐RVCZ) is an oral antifungal agent approved in Japan for the treatment of onychomycosis. We treated 36 patients (mean age 77.6 years) with onychomycosis that had been refractory to long‐term topical treatment. The patients took F‐RVCZ (100 mg ravuconazole) once daily for a mean of 11.3 weeks, and were followed up for an average of 48 weeks (mean 48.3 ± 2.1 weeks). The mean rate of improvement of the affected nail area at 48 weeks was 59.4%, and 12 patients achieved complete cure. Patients with total dystrophic onychomycosis (TDO) showed a significantly lower improvement rate than those with distal and lateral subungual onychomycosis (DLSO), and those with an affected nail area of 76%–100% at the first visit showed a significantly lower improvement rate than those with an affected nail area of 0%–75%. Six patients had adverse events necessitating treatment discontinuation, but the symptoms and laboratory data improved without specific treatment in all of them. The data suggest that F‐RVCZ would be effective in various age groups, including the elderly, and even in patients with onychomycosis refractory to long‐term topical antifungal treatment. It was also suggested that its early use in mild cases might achieve a higher rate of complete cure. Furthermore, the average cost of oral F‐RVCZ therapy was lower than that for topical antifungal agents. Therefore, F‐RVCZ is considered to be much more cost‐effective than topical antifungal agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OnychomycosisDermatologic AgentsFoot DermatosesHumansAgedAntifungal AgentsNailsLong-Term CareTreatment OutcomeAdministration, Topical

Stichwörter der Autor:innen

fosonychomycosisravuconazoleravuconazolecost-effectivenesstopical antifungal treatment

Substanzen

Antifungal AgentsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Iwate Medical University School of Medicine, Iwate, Japan.
  • Department of Dermatology, Saitama Medical University, Saitama, Japan.

ORCID-Profile: Tsuyoshi Inoue, Daisuke Watabe, Yuichiro Tsunemi

Zitieren

APA

Inoue, T., Watabe, D., Tsunemi, Y., & Amano, H. (2023). Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16824

Vancouver

Inoue T, Watabe D, Tsunemi Y, Amano H. Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16824

BibTeX
@article{Inoue2023,
  author = {Inoue, Tsuyoshi and Watabe, Daisuke and Tsunemi, Yuichiro and Amano, Hiroo},
  title = {Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16824}
}
Kostenlos starten →